Advertisement
Protexia(R), a recombinant version of human butyrylcholinesterase (BChE),is being developed as a pre- and post-exposure therapy for casualties on thebattlefield or civilian victims of nerve agent attacks. Valortim(R), inco-development with Medarex, Inc., is a fully human monoclonal antibodydesigned to treat and protect against inhalational anthrax.
Advertisement
The HHS Public Health Emergency Medical Countermeasures Enterprise(PHEMCE) Stakeholders Workshop 2008 and BARDA Industry Day will bring togetherpublic and private sector stakeholders for a dynamic dialogue on the currentstate of medical countermeasure preparedness, PHEMCE initiatives in the pastyear, and plans for moving forward to enhance national capabilities to respondto a public health emergency.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States andits allies by developing and commercializing medical countermeasures againstbiological and chemical weapons. PharmAthene's lead product developmentprograms include:
For more information about PharmAthene, please visithttp://www.PharmAthene.com.-- SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents -- RypVax(TM) - a recombinant dual antigen vaccine for plague
SOURCE PharmAthene, Inc.
